Precision Cancer Medicine Pipeline and Services

Projektinformationen

PCMPS

ID Finanzhilfevereinbarung: 673477

DOI

10.3030/673477

Projekt abgeschlossen

EK-Unterschriftsdatum 14 April 2015

Startdatum 1 Mai 2015

Enddatum 31 Oktober 2015

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

PUBGENE AS
Norway

Periodic Reporting for period 1 - PCMPS (Precision Cancer Medicine Pipeline and Services)

Berichtszeitraum: 2015-05-01 bis 2015-10-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

The Precision Medicine and Pipeline Services (PCMPS) project has demonstrated potential to become an important tool for next-generation sequencing services. PubGene in collaboration with BGI-EU aims to develop and commercialize PCMPS through the development, implementation, integration, and evaluation of tumour sample sequencing, data analysis and interpretation technology. More specifically, we envision the oncologists can use this pipeline to sequence and analyse patients’ tumour mutation profiles, to find the “actionable” mutations, and to highlight the targeted drugs available either in the market or in clinical trials. This pipeline will provide an important service towards the personalized cancer treatment, therefore benefitting both cancer patients and cancer care professionals.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

PubGene AS has together with BGI-Europe conducted several market studies using multiple techniques for investigation, including web searches, analysis of available marketing reports, analysis of annual reports from numerous stakeholders in the market and discussions with key opinion leaders. The purpose of these investigations was to obtain a better understanding of the market and market segments. We have analysed the customer categories and found that the customers of our service will first and foremost be hospitals and cancer diagnostics and treatment centers. Moreover, we have identified several factors differentiating our product/service from other suppliers in the same business space, such as competitiveness on price, geographical location, scalability and a service model with a comprehensive one-stop-shop providing full pipeline integration with existing database structures and continuous deep mining. We have developed a plan for how to develop the methods, integrating information related to biomarkers and diagnostics. We have also identified the risks with commercialization, which includes the maturation of the precision medicine market.

We have identified 5 work packages for the development plan. These will allow the project to proceed towards integrating NGS data with an existing EMR system, with the addition of data retrieval and comparison functionality to serve for clinical decision review and support. We have now also made estimations about the foreseen product launch in Q1 2019, which would include a product selection, ranging from fee-for-service to customized integration products covering the complete or individual parts of the PCMPS pipeline.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Our results have demonstrated that our services have a large potential for patients, healthcare providers and other stakeholders in the precision medicine value chain. We understand that an important consideration in this area is the interoperability between software, databases and general procedures, which alone can dictate the ability to succeed. Together with BGI-Europe, PubGene AS has conducted several market studies using multiple techniques for investigation, including web searches, analysis of available market reports, analysis of annual reports from numerous stakeholders in the business and discussions with key opinion leaders. Importantly, a successful implementation of this project will improve clinical decision-making in precision cancer medicine, and will therefore benefit both cancer patients and cancer care professionals. This has the potential to save considerable money for the healthcare sector and will allow the end-users of these services, the patients, to obtain a more precise and effective care.

pcmps.jpg